Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1F | O60840 | 10/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 10/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 10/20 | 0.59 |
| ▸ | CACNA1C | Q13936 | 10/20 | 0.59 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6347405 | 0.85 | CACNA1F (0.67) | CACNA1FCACNA1DCACNA1SCACNA1CPDE1C | |
| SCHEMBL6337588 | 0.84 | CACNA1F (0.47) | CACNA1FCACNA1DCACNA1SCACNA1CPDE1C | |
| SCHEMBL6346164 | 0.81 | PDE1C (0.62) | CACNA1FCACNA1DCACNA1SCACNA1CPDE1C | |
| SCHEMBL6339672 | 0.76 | PDE1C (0.52) | CACNA1FCACNA1DCACNA1SCACNA1CPDE1C | |
| SCHEMBL6337709 | 0.76 | ADRA1D (0.60) | CACNA1FCACNA1DCACNA1SCACNA1CPDE1C | |
| SCHEMBL6347834 | 0.76 | ADRA1D (0.60) | CACNA1FCACNA1DCACNA1SCACNA1CPDE1C | |
| SCHEMBL6339673 | 0.76 | ADRA1D (0.56) | CACNA1FCACNA1DCACNA1SCACNA1CPDE1C | |
| SCHEMBL6339676 | 0.76 | PDE1C (0.51) | CACNA1FCACNA1DCACNA1SCACNA1CPDE1C | |
| SCHEMBL6338169 | 0.76 | ADRA1D (0.56) | CACNA1FCACNA1DCACNA1SCACNA1CPDE1C | |
| SCHEMBL6338173 | 0.76 | PDE1C (0.53) | CACNA1FCACNA1DCACNA1SCACNA1CPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855716-B2 | Dihydropyrimidine compounds and compositions containing the same | AJINOMOTO CO., INC. (JP) | 2005-02-15 | — | — | US | disclosed |
| US-20020143023-A1 | Dihydropyrimidine compounds and compositions containing the same | AJINOMOTO CO. INC (JP) | 2002-10-03 | — | — | US | disclosed |
| EP-1193259-A1 | DIHYDROPYRIMIDINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2002-04-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143023-A1 | Dihydropyrimidine compounds and compositions containing the same | CACNA1B, CACNA1D, CACNA1G | CACNA1F 5/4885CACNA1D 2/4885CACNA1S 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.